226 related articles for article (PubMed ID: 27923840)
21. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
[TBL] [Abstract][Full Text] [Related]
22. [Osimertinib (Tagrisso
Giroux Leprieur E; Cortot AB; Cadranel J; Wislez M
Bull Cancer; 2016 Oct; 103(10):815-821. PubMed ID: 27641462
[TBL] [Abstract][Full Text] [Related]
23. Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
Mezquita L; Varga A; Planchard D
Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891
[TBL] [Abstract][Full Text] [Related]
24. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
25. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
26. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
27. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
Sullivan I; Planchard D
Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815
[TBL] [Abstract][Full Text] [Related]
28. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
Nanjo S; Hata A; Okuda C; Kaji R; Okada H; Tamura D; Irie K; Okada H; Fukushima S; Katakami N
Br J Cancer; 2018 Jan; 118(1):32-37. PubMed ID: 29190637
[TBL] [Abstract][Full Text] [Related]
29. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of osimertinib in a Japanese compassionate use program.
Fujiwara Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Sakiyama N; Ando Makihara R; Ohe Y
Jpn J Clin Oncol; 2017 Jul; 47(7):625-629. PubMed ID: 28419328
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
[TBL] [Abstract][Full Text] [Related]
32. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
[TBL] [Abstract][Full Text] [Related]
33. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
[TBL] [Abstract][Full Text] [Related]
34. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.
Li W; Qiu T; Guo L; Ling Y; Gao Y; Ying J; He J
Cancer Lett; 2018 Jun; 423():9-15. PubMed ID: 29524556
[TBL] [Abstract][Full Text] [Related]
35. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
Xing L; Pan Y; Shi Y; Shu Y; Feng J; Li W; Cao L; Wang L; Gu W; Song Y; Xing P; Liu Y; Gao W; Cui J; Hu N; Li R; Bao H; Shao Y; Yu J
Clin Cancer Res; 2020 Dec; 26(23):6168-6175. PubMed ID: 32817079
[TBL] [Abstract][Full Text] [Related]
37. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
Yang JC; Shepherd FA; Kim DW; Lee GW; Lee JS; Chang GC; Lee SS; Wei YF; Lee YG; Laus G; Collins B; Pisetzky F; Horn L
J Thorac Oncol; 2019 May; 14(5):933-939. PubMed ID: 30763730
[TBL] [Abstract][Full Text] [Related]
38. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
39. Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India.
Malik PS; Noronha V; Dabkara D; Maddu VK; Rajappa S; Limaye S; Batra U
Indian J Cancer; 2022 Mar; 59(Supplement):S1-S10. PubMed ID: 35343187
[TBL] [Abstract][Full Text] [Related]
40. Osimertinib: First Global Approval.
Greig SL
Drugs; 2016 Feb; 76(2):263-73. PubMed ID: 26729184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
